retatrutide ada 2025 results Phase 3: 60% Achieved Surgical-Level Weight Loss ADA 2026: TRANSCEND-T2D-1: Retatrutide Demonstrates

While the world has focused on the battle between injectables and oral tablets, the "Mucosal Frontier" addresses the three biggest hurdles in peptide therapy: 1 Bioavailability: By utilizing a mucosal delivery platform, the drug avoids first-pass metabolism in the liver, potentially offering a more efficient way for the body to utilize the peptide compared to traditional oral versions

The scientists behind these discoveries could be among the 2025 Nobel Prize winners.

This can prevent muscle wasting and support a healthier body composition

GLP-1 is a hormone your body makes

Wondering can I do my ozempic shot a day early